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Abstract
Purpose: To describe recent international trends in antiepileptic drug (AED) use dur-
ing pregnancy and individual patterns of use including discontinuation and switching.
Methods: We studied pregnancies from 2006 to 2016 within linked population-
based registers for births and dispensed prescription drugs from Denmark, Finland,
Iceland, Norway, Sweden, and New South Wales, Australia and claims data for public
and private insurance enrollees in the United States. We examined the prevalence of
AED use: the proportion of pregnancies with ≥1 prescription filled from 3 months
before pregnancy until birth, and individual patterns of use by trimester.
Results: Prevalence of AED use in almost five million pregnancies was 15.3 per 1000
(n = 75 249) and varied from 6.4 in Sweden to 34.5 per 1000 in the publicly-insured
US population. AED use increased in all countries in 2006-2012 ranging from an
increase of 22% in Australia to 104% in Sweden, and continued to rise or stabilized in
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the countries in which more recent data were available. Lamotrigine, clonazepam, and
valproate were the most commonly used AEDs in the Nordic countries, United States,
and Australia, respectively. Among AED users, 31% only filled a prescription in the
3 months before pregnancy. Most filled a prescription in the first trimester (59%) but
few filled prescriptions in every trimester (22%).
Conclusions: Use of AEDs in pregnancy rose from 2006 to 2016. Trends and pat-
terns of use of valproate and lamotrigine reflected the safety data available during
this period. Many women discontinued AEDs during pregnancy while some switched
to another AED.
K E YWORD S
antiepileptics, drug utilization, pharmacoepidemiology, population registers, pregnancy,
valproate
1 | INTRODUCTION
Antiepileptic drugs (AEDs) are used for epilepsy, bipolar disorder, neuro-
pathic pain, and migraine. Continuous treatment with AEDs, including
throughout pregnancy, is often required to prevent seizures in women
with epilepsy and relapse or recurrence in women with bipolar disorder.1,2
However, some drugs including valproate, phenytoin, and topiramate have
been found to be teratogenic.3 Therefore, women may request or be
advised by their healthcare providers to switch to another AED in prepara-
tion for a planned pregnancy or upon discovery of pregnancy. Some
women may discontinue medication altogether, risking uncontrolled illness
and associated risks.1,2 To quantify the extent of fetal exposure and
potential for uncontrolled maternal illness, it is important to understand if
and how AED use in pregnant women has changed over time.
Several AED utilization studies among pregnant women have
been published in recent years, with most including data up to
2007.4-7 These studies showed that use of AEDs increased interna-
tionally in the preceding two decades, driven by the uptake of newer
second-generation AEDs (eg, lamotrigine, topiramate, pregabalin) and
expanding approved indications and off-label use for psychiatric and
pain conditions for both first- and second-generation AEDs. One UK
study found that prescribing of valproate and lamotrigine in the
6 months before pregnancy continued to increase from 2007 to
2012.8 Another study that described the prevalence of AED use over-
all between 2004 and 2010 in seven European regions found a
decline in AED prescribing within pregnancy.9
Reports based on more recent data are needed to understand
changes in AED use with a focus on patterns of use in and around
pregnancy for AEDs overall and specific drugs. In particular, attention
should be paid to patterns of use of valproate in pregnancy, following
the US Food and Drug Administration's 2011 and 2013 Safety
Announcements10,11 and the European Medicine Agency's (EMA)
2014 recommendation12 for more restrictions on the use of valproate
in women and girls. This is due to the now recognized neu-
rodevelopmental impacts on offspring, in addition to the well-known
risk of congenital malformations.13
The purpose of this study is to describe AED use during preg-
nancy in recent data from the five Nordic countries (Denmark, Fin-
land, Iceland, Norway, and Sweden), New South Wales (NSW), the
most populous state in Australia, and the United States. In addition,
we sought to describe the individual patterns of use in pregnancy
including the extent of discontinuation, AED polytherapy, and
switching between AEDs.
2 | MATERIALS AND METHODS
This study is based on data from the nationwide prescription and
medical birth registers in Denmark, Finland, Iceland, Norway, and
KEY POINTS
• Some antiepileptic drugs (AEDs) including valproate are
recognized teratogens but many women require treat-
ment in pregnancy
• Among 4.9 million pregnancies from 2006-2016 in linked
population-based registers (Nordic countries and Austra-
lia) and claims databases (United States), prevalence of
any AED use and specific drugs varied widely
• Any AED use ranged from 6.4 (Sweden) to 12.6 (Austra-
lia), and up to 34.5/1000 pregnancies (United States), and
increased in all countries during the study period, while
few had continuous use in pregnancy
• Valproate use in pregnancy declined from 2006 to 2016
in the Nordic countries and United States, but not in Aus-
tralia where it was the most commonly used AED
• This study provides important information about recent
trends and treatment patterns of AEDs during pregnancy
on three continents
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Sweden, and data from NSW, Australia and two US insurance claims
databases (Table S1). The start of the study period was 2006 with the
aim to present the use and patterns up to as recent as possible.
2.1 | Data sources
Personal identity numbers in the Nordic countries allowed for determin-
istic linkage of data from the medical birth registers to prescribed drug
registers, which capture all prescribed drugs dispensed in pharmacies.
These registers in the Nordic countries cover the entire population in
each country (general population). The Australian data were probabilisti-
cally linked,14 and the study population was restricted to pregnancies
among concessional beneficiaries (eligible due to low income, chronic ill-
ness, or disability) who have complete pharmaceutical dispensing data
(20.3% of births in NSW, 2006-2012). The US data were linked based on
a unique enrollment identifier and cover a large population of privately-
and publicly-insured individuals from all regions of the United States.
The Truven Health MarketScan Commercial Claims and Encounters
Database contains healthcare claims for privately-insured individuals
enrolled in various employer-sponsored health plans.15 The Medicaid
Analytic eXtract Database (MAX) includes claims from publicly-insured
individuals from 46 states and the District of Columbia (mandatory cov-
erage for low income families and individuals with disability).16
2.2 | Study population
The study included all pregnancies with a gestational age of at least
22 weeks resulting in a live birth or stillbirth. Each pregnancy had a
minimum coverage in the prescription data from 90 days before the
first day of the last menstrual period (LMP) to birth. For the US MAX
database and for secondary analyses for all countries regarding timing
of use in the 6 months before and after pregnancy, we included preg-
nancies that had prescription data covering 180 days before LMP to
180 days after birth.
2.3 | AED use
We defined use of AEDs in pregnancy as individuals filling at least one
prescription for a drug in the Anatomical Therapeutic Chemical (ATC)
group N03A (antiepileptics) from 90 days before LMP until the end of
pregnancy.17 In the US databases, drugs were identified by the
generic drug names. We classified use of any AED, lamotrigine, val-
proate, pregabalin, carbamazepine, levetiracetam, topiramate,
oxcarbazepine, clonazepam, gabapentin, and the remaining AEDs
grouped together as other AEDs, according to drugs dispensed in the
following periods: 3 months before pregnancy (PRE, LMP-90 to LMP-
1 day), first trimester (T1, LMP to LMP + 97 days), second trimester
(T2, LMP + 98 to LMP + 202 days), and third trimester (T3, LMP
+ 203 days to birth). We chose lamotrigine, valproate, and carbamaze-
pine for more in-depth analysis because they are used as both
anticonvulsants and mood stabilizers. We defined selected patterns of
use of interest based on prescription fills (yes/no) in the periods
described above (PRE, T1, T2, T3) (Box 1).
We defined polytherapy as prescription fills for two or more dis-
tinct AEDs in the same pregnancy trimester (T1, T2, or T3) and mon-
otherapy as prescription fills for only a single AED in each exposed
pregnancy trimester. We defined switching as discontinuation of one
AED and initiation of another AED. This was operationalized as no
prescription fills for the second AED before the last trimester in which
the first AED was filled, and with fills for the second AED in at least
one trimester after the last trimester of the first AED.
We conducted sub-analyses on reimbursement indications in the pre-
scription data from Finland and Norway to characterize patterns of discon-
tinuation for AED users with epilepsy, bipolar disorder, or other conditions.
2.4 | Maternal and pregnancy characteristics
We examined the following characteristics for all pregnancies where
available: country and year of birth, maternal age at delivery, parity,
smoking status; marital/cohabitation status, multiple pregnancy, preg-
nancy outcome (live birth, stillbirth; in the case of multiple pregnan-
cies where one or more infants died, the pregnancy was grouped with
stillbirths), and gestational age at birth in completed weeks. For
women with AED use, we described co-medication with other psy-
chotropic drugs (≥1 prescription fill from LMP-90 to birth; yes/no).
2.5 | Data analysis
We examined the proportion of users of any AED and specific AEDs
anytime in pregnancy (prevalence per 1000 pregnancies) by year of
birth, maternal age, and pregnancy outcome (preterm birth and still-
birth) for any AED. We tested for trends in the proportion of users
Box 1 Exposure definitions of interest
• Any pregnancy use = 1 or more prescription fills from
LMP-90 to birth (PRE, T1, T2, T3)
• Polytherapy = prescription fills for 2 or more distinct
AEDs in a single pregnancy trimester
• Switching = discontinuation of one AED, initiation of
another
• Discontinuation = prescription fill in PRE or T1, but not
after
• Early discontinuation = prescription fill in PRE only; no
refill within pregnancy
• First trimester exposure = prescription fill in T1,
irrespective of other periods
• Initiation = prescription fill in T2 or T3, but not before
• Continuous use = prescription fill in each trimester, T1,
T2, and T3
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across years, maternal age categories, and pregnancy outcomes.
Among women with any AED use in pregnancy, we calculated the pro-
portion (%) with selected patterns of use: early discontinuation, first tri-
mester use, initiation after first trimester, and continuous pregnancy use
(Box 1). We calculated the absolute change in AED use per 1000 preg-
nancies from the first to last year of data available for each data source
(and to 2012 for all countries), the relative change (%) in AED use, and
annual increase (%). We described the most commonly used specific
drugs in each country, the use of specific drugs in polytherapy regimens,
proportion of users of specific drugs who discontinued use before the
first and second trimesters, and the number of users switching AED
treatment to/from specified drugs. Finally, we compared the prevalence
of any AED use during an extended time window of 6 months before
and after pregnancy. Analyses were performed separately and pooled
across countries by summing counts from aggregated data.
3 | RESULTS
The pooled prevalence of any AED use in 4 924 536 pregnancies was
15.3 per 1000 (n = 75 249) and varied widely, ranging from 6.4
(Sweden) to 10.7 (Iceland) in the Nordic countries, to 12.6 in NSW,
Australia, and up to 34.5/1000 in the US MAX database (Table 1).
Among users, AED polytherapy in pregnancy was lowest in Iceland
(9%) and highest in Australia (15%). AED use was higher in the youn-
gest (≤24 years) and oldest women (≥40 years), with some variation
by country (Table S2). Characteristics of the overall study population
of pregnancies for all countries/databases are summarized in
Table S3. Pregnant women in the US MAX database and NSW,
Australia were more likely to be younger than in the Nordic countries
and US MarketScan. Characteristics of AED users in each country or
database are presented in Tables S4-S11. Women who used AEDs in
pregnancy were more likely to be smokers, less likely to cohabitate
with a partner, and there was a high prevalence of co-medication with
other psychotropic drugs, in particular antidepressants.
AED use increased from 2006 to 2012 in all countries, and con-
tinued to rise or stabilized in countries with more recent data
(Figure 1). This ultimately represented a relative increase in use of
22% (3.3% annually) in Australia to 104% (8.2% annually) in Sweden.
Lamotrigine was consistently the most commonly used AED in the
Nordic countries where use increased by 1.5/1000 pregnancies (rela-
tive increase 78%) from 2006 to 2012 and continued to increase
thereafter. Use of lamotrigine also increased in NSW, Australia and
US MAX, but not in US MarketScan (2012-2015). Clonazepam was
the most commonly used AED in the United States, with higher use
than in the Nordic countries or NSW, Australia. Its use increased in
US MAX by 2.5/1000 (31%) by 2013 and was mostly stable around
7/1000 in US MarketScan. Valproate was the most commonly used
AED in NSW, Australia, with higher use than in the Nordic countries
and United States. Valproate use decreased by 0.2/1000 (−21%) in
the Nordic countries by 2012, 0.9/1000 (−18%) in US MAX by 2013
and by 0.2/1000 (−26%) in US MarketScan but no decrease was
observed in NSW, Australia, by 2012. Topiramate use increased by
0.1/1000 (19%) in the Nordic countries and more substantially in
Australia (1.1/1000, 376%) by 2012. However, use was higher in the
United States and increased by 3.3/1000 (76%) in US MAX by 2013
and by 0.9/1000 (20%) from 2012 to 2015 in US MarketScan.
Pregabalin use increased by 1.2/1000 (474%) in the Nordic countries
by 2012 and in US MAX (1.7/1000), whereas use decreased by
0.2/1000 (−21%) in US MarketScan.
Among women with AED use, 31% had early discontinuation
(Figure 2). This varied somewhat by country (19%-38% for any AED)
(Figure S1). Most of the AED users filled a prescription in the first tri-
mester and few initiated after the first trimester. A minority of the
AED users had prescription fills in every trimester; continuous use
through pregnancy was highest for lamotrigine and lowest for
TABLE 1 Composition of the overall study population and prevalence of use of antiepileptic drugs in pregnancy





N % Na per 1000 Nb per 1000 % Nb per 1000 %
Total 4 924 536 100 75 249 15.3 45 565 9.3 88 6265 1.3 12
Denmark 660 560 13.4 4547 6.9 3335 5.0 90 358 0.5 10
Finland 634 528 12.9 6022 9.5 4116 6.5 87 601 0.9 13
Iceland 32 267 0.7 346 10.7 197 6.1 91 19 0.6 9
Norway 590 168 12.0 4141 7.0 2830 4.8 89 361 0.6 11
Sweden 1 028 732 20.9 6630 6.4 4580 4.5 89 580 0.6 11
NSW Australia 114 360 2.3 1442 12.6 914 8.0 85 157 1.4 15
US MarketScan 855 763 17.4 17 388 20.3 9614 11.2 90 1086 1.3 10
US MAX 1 008 158 20.5 34 733 34.5 19 979 19.8 87 3103 3.1 13
Abbreviations: AED, antiepileptic drug; MAX, Medicaid Analytic Extract database; NSW, New South Wales; US, United States.
aAt least one prescription filled from 3 months before pregnancy to birth.
bMonotherapy and polytherapy do not sum to any AED use because they exclude pregnancies with prescription fills only in the 3 months before
pregnancy.
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F IGURE 1 Prevalence of antiepileptic drug use per 1000 pregnancies, by year of birth. Pregnancy exposure defined as ≥1
prescription filled from 3 months before pregnancy to birth. One or more years had <5 exposed pregnancies for valproate (Iceland),
carbamazepine (Iceland), levetiracetam (Iceland), pregabalin (Denmark, Iceland), gabapentin (NSW Australia, Iceland), clonazepam (NSW
Australia, Iceland), topiramate (Iceland), oxcarbazepine (NSW Australia, Iceland, Sweden), and other AEDs (Finland, Iceland, Norway).
Pregabalin was not reimbursed during the period of 2006–2012 in Australia and is therefore not included for NSW Australia. AED,
antiepileptic drug [Colour figure can be viewed at wileyonlinelibrary.com]
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valproate, most common in Denmark (49%), least common in Iceland
(13%) followed by the United States. In United States, only 5%-8% of
valproate users filled prescriptions in every trimester, while it was
11% in Australia and 14%-39% in the Nordic countries.
Prevalence of AED use was highest before pregnancy, declined
throughout pregnancy reaching 27%-70% of pre-pregnancy use in
the third trimester, then rebounded after pregnancy to levels
between first and second trimester use by 3 months, and not yet
reaching pre-pregnancy levels by 6 months (Figure 3). Among the
Nordic countries, the use of AEDs decreased during pregnancy most
substantially in Iceland, becoming more in line with use in the other
Nordic countries, with a similar trend observed for the US
F IGURE 2 Selected patterns of antiepileptic drug use in pregnancy. These selected patterns are not mutually exclusive (continuous
pregnancy use is a subset of the first trimester exposed) and they do not cover all 15 mutually exclusive categories of AED use by period (yes/no
in PRE, T1, T2, T3). 4% of AED exposed (PRE + T2, PRE + T2 + T3, PRE + T3) did not fit any of the selected patterns [Colour figure can be viewed
at wileyonlinelibrary.com]
F IGURE 3 Timing of antiepileptic drug use surrounding pregnancy. The bars show the prevalence of use in each period and the lines show
the number of users in each period, relative to the number of users in 0-3 months before pregnancy in a subset of the study population with
prescription data covering 6 months before pregnancy to 6 months after birth, where available (Ns: Denmark 629 986, Finland 634 528, Iceland
32 267 [same as primary study population], Norway 561 014, Sweden 983 176, NSW Australia 111 488, US MarketScan 851 077, US MAX
1008158 [same as primary study population]) [Colour figure can be viewed at wileyonlinelibrary.com]
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databases, which had the highest absolute prevalence of AED use
in every time period.
Use of lamotrigine and carbamazepine showed less variation
during pregnancy than valproate for which the number of users
declined substantially during pregnancy, but there was an increase
in T3 for some countries (Figure S2). There was also a more consis-
tent decrease in use before pregnancy for valproate than
lamotrigine or carbamazepine. Valproate and carbamazepine use
after pregnancy reached levels closer to pre-pregnancy than
lamotrigine.
In the Nordic countries, lamotrigine was used in 3/1000 preg-
nancies, followed by pregabalin, valproate, and carbamazepine, each
with around 1 exposed per 1000 pregnancies and the group of
other AEDs was infrequently used, mostly as part of AED poly-
therapy regimens (Table 2). In NSW, Australia and the United
States, there was higher use of other AEDs. In NSW, Australia, val-
proate was used in more than 6/1000 pregnancies and was higher
than carbamazepine (3.6/1000) and lamotrigine (2.1/1000), but was
the most commonly discontinued AED. In the United States, clonaz-
epam and topiramate use was much higher than in the Nordic coun-
tries and Australia and less commonly part of polytherapy.
Pregabalin and gabapentin were infrequently used in polytherapy
and commonly discontinued. More details on country-specific use
of individual AEDs is presented in Tables S12-S19. Finland had high
levels of switching, whereas switching was infrequent in Iceland and
NSW, Australia. In general, more than twice as many switched from
valproate or topiramate to another drug than to these drugs. The
only drugs more commonly switched to, than switched from, were
levetiracetam and lamotrigine. As a proportion of its overall preg-
nancy use, levetiracetam was the most commonly initiated or
switched to AED in pregnancy. Overall, 46% of pregnancies with
AED polytherapy included lamotrigine, 29% included levetiracetam,
and 19% included valproate (Table S20).
Based on indications for reimbursement in Norway and Finland,
48% of women with any AED use had epilepsy and of those, 16%
(Norway) and 4% (Finland) discontinued use. In contrast, 63% of
women with bipolar disorder and 70% with other conditions discon-
tinued AEDs (data not shown). In both Norway and Finland, women
with epilepsy were least likely to discontinue oxcarbazepine,
levetiracetam, and lamotrigine and most likely to discontinue
topiramate, pregabalin, and gabapentin. The proportion using AEDs
for other indications increased over the study period.
4 | DISCUSSION
Using high-quality data from seven countries and including almost five
million pregnancies, we described prevalence trends and individual
patterns of use in over 75 000 AED users in recent years. We
observed that in each country, AED use in pregnancy has increased
since 2006. Lamotrigine was the most commonly used AED in the
Nordic countries and its use increased in all countries. Pregabalin use
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commonly used AED in pregnancy in the Nordic countries and use may
have peaked during the study period. Topiramate use also increased in
all countries and was substantially higher in the United States than in
the Nordic countries or Australia. Clonazepam was the most commonly
used drug in the United States, far exceeding use in the Nordic countries
or Australia and partially accounts for the higher overall AED use in the
United States. Clonazepam is a benzodiazepine and its use mirrors the
wider trend of high and increasing use of benzodiazepines in the United
States.18 Valproate use decreased in most countries since 2006 but
remained steady in Australia as the most commonly used AED in preg-
nant women. Valproate use in Finland was about twice as high as in the
other Nordic countries, but use has fallen sharply in the most recent
years. The trends for 2006-2016 suggest there may be ongoing declines
in use of valproate, carbamazepine, and other AEDs and ongoing
increases in use of gabapentin and levetiracetam in pregnancy.
We observed that around one-third of women with AED use only
filled a prescription before but not during pregnancy. While the major-
ity of the AED users filled a prescription in the first trimester, a minor-
ity continued to use AEDs in each pregnancy trimester. This picture
has been described for other psychotropic drugs used for chronic con-
ditions.19,20 Discontinuation of AEDs was common, in particular for
the drugs pregabalin and gabapentin, which are more frequently used
to treat pain.21 Initiation of use during pregnancy was more common
for valproate than lamotrigine or carbamazepine. This may suggest
that valproate use was avoided in the first trimester, but not necessar-
ily later in pregnancy, when it could still exert negative effects on fetal
brain development.22,23 Valproate is among the most effective drugs
for seizure control24 and the only effective medication for certain
patients with epilepsy or bipolar disorder. Untreated epilepsy and
bipolar disorder are associated with perinatal risks, so AED discontinu-
ation may not be the safest option for many patients.1,25 Switching
and discontinuation patterns suggested an effort to decrease the
number of drugs being used in pregnancy and switch to safer alterna-
tives when possible (namely, from valproate and topiramate, and to
lamotrigine and levetiracetam).3,24 Observed patterns of use suggest
the need for more pre-pregnancy counseling to encourage adjust-
ments to treatment before pregnancy.
4.1 | Strengths and limitations
A strength of this study is that it covered the entire population in the
Nordic countries. Unlike the Nordic data, it is not clear if AED use in
Australia is higher than in the Nordic countries in general, or only in
this population, restricted to concessional beneficiaries who may qual-
ify due to disability. However, a publication from Australia reporting
data from 2000 to 2011 showed that valproate use in the general
population was higher than carbamazepine or lamotrigine.26 Similarly,
for the United States, MAX includes all women on Medicaid, the pub-
lic insurance that covers almost 50% of the deliveries, and the data
from private insurance in MarketScan represents the other half of the
population. AED use is likely to be higher among women enrolled in
MAX than in the general population because disability is one of the
reasons for eligibility, but we can reasonably infer US national trends
and patterns of AED use from these data. The inclusion of recent data
for a privately-insured US population shows that AED use is higher in
the United States in general and that trends of increasing use may
have slowed in the most recent years. Our study was restricted to live
births and stillbirths (US MAX database only live births), and if AED
use is associated with miscarriage or abortion, actual use in pregnancy
could be higher than what we observed in the included study
population.
The use of AEDs in pregnancy is inferred based on prescriptions
filled at the pharmacy, and we do not know if the medication was con-
sumed or precisely when, though, records of filled prescriptions are
one step closer to actual use than prescribing records.27 Additionally,
filled prescriptions are not subject to recall bias. However, our defini-
tions of polytherapy and switching could be sensitive to the assump-
tion that prescription filling patterns represent use of the medication
at that time.
We did not have information on the exact indication for AED use.
A US study of pregnancy use of AEDs in 2001 to 2007 reported that
21% had epilepsy, 48% psychiatric disorder, 22% pain disorder, and
20% had no diagnosis suggesting indication during or in the 6 months
prior to pregnancy.6 When we explored indication for reimbursement
in Norway and Finland, about half used AEDs for indications other
than epilepsy, with the proportion increasing over the study period.
Overall, we observed similar individual patterns of use as reported in a
recent Danish study, which focused on AEDs defined as mood stabi-
lizers with exclusion of women with epilepsy.28 In a study that evalu-
ated use of AEDs in pregnant women with epilepsy in 38 countries,
there was more AED polytherapy (up to 30%)4; roughly double what
we observed in the general population. Our findings suggest that AED
use for non-epilepsy indications further expanded from 2006 to 2016
and predominated the observed patterns of use.
4.2 | Conclusions and implications
Reasons for the most striking differences in AED use between coun-
tries may include differences in reimbursement policies, prevalence of
use for indications other than epilepsy and off-label use, guideline rec-
ommendations, contraindications, and local factors including medical
culture. Higher use of gabapentin in the United States may reflect an
effort to use alternative pain medications in the context of the recent
opioid use epidemic and more off-label use.
The persistent use of valproate in pregnancy during this period
and the relatively high use in Finland and Australia are noteworthy.
International health authorities (eg, Health Canada, FDA, EMA) have
issued safety warnings regarding neurodevelopmental problems asso-
ciated with valproate in pregnancy since at least 2011. In Australia,
lamotrigine and clonazepam are subsidized for epilepsy only; in con-
trast, carbamazepine and valproate have no restrictions on their use.
Therefore, reimbursement policies may incentivize treatment with val-
proate or carbamazepine, rather than lamotrigine, which is only reim-
bursed for epilepsy but may be a safer alternative for use in pregnant
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women with bipolar disorder.29 Furthermore, it appears that interna-
tional safety alerts may contribute to decreasing valproate use in
pregnancy; we observed a sharper decrease in Finland since the EMA
published an assessment in October 2014, sent out leaflets to pre-
scribing physicians, issued product warnings, and introduced risk mini-
mization measures.12 New regulations may contribute to future
declines in use. In March 2018, EMA banned the use of valproate for
migraine in girls or women of reproductive age, and strongly discour-
aged use in this population for bipolar disorder or epilepsy unless
there is no other effective treatment.30 These policy changes both
strengthen restrictions and increase requirements to inform women
and girls of the risks. However, it is unlikely that all exposure in preg-
nancy can be completely avoided.
The increased use of AEDs in pregnancy in recent years suggests
the need for further comparative safety studies to inform the balance of
risks and benefits for use of different AEDs as well as those of modifica-
tion, or discontinuation of treatment in pregnancy. Future studies could
explore whether women who discontinue AEDs switch to alternative
treatments. While there is convincing evidence that valproate is associ-
ated with harm, it is important to continue to study the long-term neu-
rodevelopmental outcomes in children exposed to AEDs in pregnancy
to guide clinical and policy decision-making in the future.
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